PPT-A GLP-1 Receptor Agonist CV Outcomes Trial

Final Results Background Trends in the Prevalence of Complications among US Adults with Newly Diagnosed Diabetes Fang M amp Selvin E Diabetes Care 202144699706 0003 lt0001 030. Zak Fallows. pharmacology@mit.edu. 2013-11-23. ESP Splash (Saturday). These slides are available online, along with fun 5-minute quizzes and other materials:. http://. datb.mit.edu. /. Are You in the Right Room?. A Selective Overview. Carl Rosow, M.D., Ph.D.. Disclosures. Consultant – Salix Pharmaceuticals. Topics for Today. Pharmacodynamics. Receptors, potency, efficacy. Agonists, antagonists. The dose response curve. Therapies in Type 2 Diabetes. DR.M.Mukhyaprana. . Prabhu. Professor of Internal Medicine. Kasturba. Medical College, . Manipal. ,. Manipal. University, India. 2. nd. International Endocrine Conference. Program Overview. Pathophysiology of Hyperglycemia. Updated ADA/EASD Standard of Care, 2017. Delays in Intensification of Therapy. The Role of Basal Insulin and GLP-1 RA in Controlling Hyperglycemia. Structure activity relationship (SAR)of sympathomimetic amines, Adrenergic antagonist and Neurone blockers Dr. ISHOLA I.O. PHARMACOLOGY, THERAPEUTICS AND TOXICOLOGY CMUL INTRO Phenylethylamine can viewed as parent compound, NA, AD, DA, ISOP Lectures. Drug Mechanisms. Receptor Interactions. Pharmacokinetics. Pharm definitions and drug selectivity. Drug= A chemical substance that interacts with a biological substance to produce a physiological effect. Rita Turnaturi. 1*, . Carmela Parenti. 2. , Girolamo Calò. 3. , Santina Chiechio. 2. , Agostino Marrazzo. 1. and Lorella Pasquinucci. 1. 1. Department of Drug Sciences, Medicinal Chemistry Section, University of Catania, Catania, Italy . VBC-612. Unit-1. P.G.. 16.10.2020. 28.10.2020. Nuclear receptors . are intracellular proteins expressed in the nucleus of a cell that have a binding site for a particular steroid molecule. . Nuclear receptors . Archana Vidya Boopathy,. 1. Anurag Nekkalapudi,. 1. Bhawna Sharma,. 1. Sophie Schulha,. 2. . Raphaela. Wimmer,. 2. Debi Jin,. 1. Janette Sung,. 1. Jeffrey Murry,. 1. Mark Nagel,. 1. Brian Carr,. Ketamine and PCP . – glutamate receptor antagonists. LSD . – serotonin receptor agonist. Alcohol. – GABA-A and . GABA-B receptor agonist (also NMDA receptor antagonist). MDMA. – increases activity of serotonin, dopamine and noradrenaline by enhancing their release and/or inhibiting reuptake. Biopsy-Confirmed DIO Mouse Model. JJ Nestor. 1. , K Rigbolt. 2. , M Feigh. 2. , D Parkes. 3. , MS Harris. 1. , 1. Altimmune, Inc., Gaithersburg, MD; 2. Gubra, Horsholm, Denmark; 3. DGP Scientific, Del Mar, CA. Pharmacodynamics. Dennis Paul, Ph.D.. dpaul@lsuhsc.edu. Learning Objectives:. Understand the theoretical basis of drug-receptor interactions.. Understand the determinants and types of responses to drug-receptor interactions.. Graded Dose-response . Relationships:. Agonist drugs mimic the action of the original endogenous ligand for the receptor (for example, isoproterenol mimics norepinephrine on β1 receptors of the heart). . Diabetes Management . for the Cardiologist. Confidential. Do Not Distribute. 1. To understand the physiologic relationships between cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (DM), and review the statistics behind the risk.